Bayer Receives U.S. FDA Breakthrough Therapy Designation for BAY 2927088 for Non-Small Cell Lung Cancer Harboring HER2 Activating Mutations

Berlin, Germany, February 26, 2024– Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials